Bolt Biotherapeutics (NASDAQ:BOLT) Cut to Hold at Zacks Research

Bolt Biotherapeutics (NASDAQ:BOLT) was downgraded by research analysts at Zacks Research from a “strong-buy” rating to a “hold” rating in a report issued on Thursday,Zacks.com reports.

BOLT has been the subject of a number of other research reports. Lake Street Capital increased their target price on Bolt Biotherapeutics to $75.00 and gave the stock a “buy” rating in a report on Friday, August 15th. Weiss Ratings restated a “sell (e+)” rating on shares of Bolt Biotherapeutics in a report on Wednesday, October 8th. Finally, HC Wainwright set a $7.00 price objective on Bolt Biotherapeutics and gave the company a “buy” rating in a research note on Monday, October 20th. Two equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $34.00.

Bolt Biotherapeutics Stock Performance

Shares of NASDAQ:BOLT opened at $4.74 on Thursday. The firm’s 50 day simple moving average is $5.39 and its 200 day simple moving average is $5.71. Bolt Biotherapeutics has a fifty-two week low of $4.41 and a fifty-two week high of $13.00. The company has a market capitalization of $9.10 million, a price-to-earnings ratio of -0.21 and a beta of 0.93. The company has a debt-to-equity ratio of 0.65, a current ratio of 3.57 and a quick ratio of 3.57.

Bolt Biotherapeutics (NASDAQ:BOLT) last issued its quarterly earnings data on Wednesday, November 12th. The company reported ($3.72) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($5.07) by $1.35. The firm had revenue of $2.17 million for the quarter, compared to analyst estimates of $0.82 million. As a group, sell-side analysts forecast that Bolt Biotherapeutics will post -1.61 earnings per share for the current year.

Institutional Trading of Bolt Biotherapeutics

Large investors have recently modified their holdings of the stock. Squarepoint Ops LLC increased its position in shares of Bolt Biotherapeutics by 19.8% in the third quarter. Squarepoint Ops LLC now owns 14,836 shares of the company’s stock worth $79,000 after purchasing an additional 2,448 shares during the period. Shay Capital LLC bought a new stake in Bolt Biotherapeutics during the third quarter worth about $85,000. Finally, Susquehanna International Group LLP acquired a new stake in Bolt Biotherapeutics during the third quarter worth about $89,000. 86.70% of the stock is owned by institutional investors and hedge funds.

About Bolt Biotherapeutics

Bolt Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company’s lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer.